GlassScriptPhysician profile
Joane Buteau
NPI 1386195345
$5,490.39
in general payments reported to CMS, 2019-2025
40 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $457 · 2022: $777 · 2023: $777 · 2024: $1,907 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,255.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $754.34 | 2021-2025 | |
| Lilly USA, LLC | $504.61 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $499.61 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Paratek Pharmaceuticals, INC. | $389.36 | 2024-2025 | Nuzyra |
| Otsuka America Pharmaceutical, INC. | $367.48 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.01 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $276.51 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Astellas Pharma US INC | $236.36 | 2023-2025 | Veozah |
| Pfizer INC. | $219.23 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $198.62 | 2021-2025 | Airsupra, Farxiga |
| Vanda Pharmaceuticals INC. | $172.45 | 2024-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $159.15 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $156.26 | 2022 | |
| Glaxosmithkline, LLC. | $136.46 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $123.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joane Buteau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.